622 related articles for article (PubMed ID: 13677268)
21. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
22. Optimizing treatment of chronic myeloid leukemia: a rational approach.
Stone RM
Oncologist; 2004; 9(3):259-70. PubMed ID: 15169981
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Borthakur G; Cortes JE
Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker BJ; Talpaz M; Resta DJ; Peng B; Buchdunger E; Ford JM; Lydon NB; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers CL
N Engl J Med; 2001 Apr; 344(14):1031-7. PubMed ID: 11287972
[TBL] [Abstract][Full Text] [Related]
25. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
26. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
27. [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Müller MC; Lahaye T; Hochhaus A
Dtsch Med Wochenschr; 2002 Oct; 127(42):2205-7. PubMed ID: 12397549
[TBL] [Abstract][Full Text] [Related]
28. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
29. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
[TBL] [Abstract][Full Text] [Related]
31. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
[TBL] [Abstract][Full Text] [Related]
32. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
33. Chronic myelogenous leukemia.
Mauro MJ; Druker BJ
Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
[TBL] [Abstract][Full Text] [Related]
34. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
35. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
36. [Chronic myeloid leukemia and tyrosine kinase inhibitors].
Mahon FX
Rev Med Interne; 2001 Sep; 22(9):894-9. PubMed ID: 11599196
[TBL] [Abstract][Full Text] [Related]
37. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
39. [Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Burchert A; Neubauer A
Internist (Berl); 2011 Mar; 52(3):283-93; quiz 294-5. PubMed ID: 21253680
[TBL] [Abstract][Full Text] [Related]
40. Treatment of chronic myeloid leukemia with imatinib mesylate.
Ohno R
Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
